Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report)'s share price was down 2.6% during mid-day trading on Thursday . The stock traded as low as $0.35 and last traded at $0.38. Approximately 36,840,297 shares changed hands during mid-day trading, an increase of 23% from the average daily volume of 30,057,420 shares. The stock had previously closed at $0.39.
Wall Street Analyst Weigh In
Separately, StockNews.com initiated coverage on shares of Tonix Pharmaceuticals in a report on Monday. They set a "hold" rating on the stock.
View Our Latest Report on TNXP
Tonix Pharmaceuticals Trading Down 4.0 %
The firm has a 50 day moving average price of $0.22 and a two-hundred day moving average price of $0.41. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07. The company has a market cap of $69.15 million, a price-to-earnings ratio of -0.01 and a beta of 2.23.
Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The firm had revenue of $2.82 million during the quarter, compared to analyst estimates of $2.63 million. As a group, equities analysts forecast that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current year.
About Tonix Pharmaceuticals
(
Get Free Report)
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
Read More
Before you consider Tonix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tonix Pharmaceuticals wasn't on the list.
While Tonix Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
